UCB Buys Candid Therapeutics in $2.2 Billion Deal to Boost Autoimmune Drug Pipeline!
Belgian pharma company UCB has announced that it will acquire Candid Therapeutics for up to $2.2 billion. This has to be one of the biggest biotech deals of early May in 2026!
It had acquired Neurona Therapeutics in the mid of April in the potential $1.15 billion deal. For UCB, Candid follows closely behind Neurona Therapeutics, which the Belgian company acquired in mid-April for $650 million upfront and the promise of up to $500 million in milestones. Neurona brings to UCB the cell therapy NRTX-1001, currently in Phase 1/2 development for drug-resistant unilateral and bilateral mesial temporary lobe epilepsy.
The deal is said to be including an upfront payment of around $2 billion, with an additional $200 million tied to future milestones, which actually indicates that UCB will pay more if the drugs under development meet certain goals in clinical trials and approvals.
UCB’s Focus on Autoimmune Diseases
The main reason behind this acquisition is to strengthen UCB’s work in treating autoimmune diseases. These are conditions where the body’s immune system attacks its own healthy cells. Examples include diseases like lupus and rheumatoid arthritis.
Candid Therapeutics is working on new types of treatments that aim to control the immune system in a more precise way. One of their key drugs, currently in early-stage testing, is designed to target immune cells and reduce harmful activity without affecting the entire immune system.
New Technology Driving Big Deals
A big highlight of this UCB’s deal is the technology Candid is developing. The company is focused on T-cell engager therapies and bispecific antibodies. These are advanced types of biologic drugs that can connect immune cells to specific targets in the body.
Even though Candid does not yet have an approved drug in the market, its technology has strong potential. This is one of the main reasons why it attracted such a high valuation.
Part of a Bigger Trend
This deal is not happening in isolation. According to multiple reports, 2026 is already seeing a rise in mergers and acquisitions in the biotech industry. Large pharmaceutical companies are under pressure to replace older drugs that are losing patent protection. As a result, UCB is looking for new and innovative treatments by acquiring smaller biotech companies.
Industry coverage from platforms like MarketScreener and TradingView also points out that such deals are becoming more common, especially in areas like immunology, cancer, and gene therapy.
What This Means for the Future
For UCB, this acquisition is a step toward building a stronger pipeline of future drugs. The company hopes that Candid’s research will lead to new treatments that can help patients with difficult autoimmune conditions.
For the biotech industry, this deal shows a clear trend: innovation is being valued more than ever. Companies with strong ideas and new technologies can attract huge investments, even at early stages.
